Highly specific role of the insulin receptor in breast cancer progression

Endocrine-Related Cancer

Volumn 22, Issue 2, 2015, Pages 145-157

  Rostoker, Ran ^a   Abelson, Sagi ^a   Bitton Worms, Keren ^a   Genkin, Inna ^a   Ben Shmuel, Sarit ^a   Dakwar, Maria ^a   Orr, Zila Shen ^a   Caspi, Avishay ^a   Tzukerman, Maty ^a   LeRoith, Derek ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer and CD24; Hyperinsulinemia; Insulin receptor; Insulin like growth factor 1 receptor

Indexed keywords

CD24 ANTIGEN; INSULIN; INSULIN RECEPTOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; CD24A PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HYPERINSULINEMIA; MAMMARY GLAND FAT; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STIMULATION; WILD TYPE; ANIMAL; DNA MICROARRAY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD24; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; INSULIN; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TUMOR BURDEN;

EID: 84929337178     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0490     Document Type: Article

References (46)

1. Abelson S 2014 Eureka-DMA: an easy-to-operate graphical user interface for fast comprehensive investigation and analysis of DNA microarray data. BMC Bioinformatics 15 53. (doi:10.1186/1471-2105-15-53)
2. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M & Brauch H 2005 Prevalence of CD44C /CD24K /low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clinical Cancer Research 11 1154-1159.
3. Akashi T, Shirasawa T & Hirokawa K 1994 Gene expression of CD24 core polypeptide molecule in normal rat tissues and human tumor cell lines. Virchows Archiv 425 399-406. (doi:10.1007/BF00189578)
4. Avruch J 1998 Insulin signal transduction through protein kinase cascades. Molecular and Cellular Biochemistry 182 31-48. (doi:10.1023/A:1006823109415)
5. Belardi V, Gallagher EJ, Novosyadlyy R & LeRoith D 2013 Insulin and IGFs in obesity-related breast cancer. Journal of Mammary Gland Biology and Neoplasia 18 277-289. (doi:10.1007/s10911-013-9303-7)
6. Belfiore A, Frittitta L, Costantino A, Frasca F, Pandini G, Sciacca L, Goldfine I & Vigneri R 1996 Insulin receptors in breast cancer. Annals of the New York Academy of Sciences 784 173-188. (doi:10.1111/j.1749-6632.1996.tb16235.x)
7. Belfiore A, Frasca F, Pandini G, Sciacca L & Vigneri R 2009 Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Reviews 30 586-623.(doi:10.1210/er.2008-0047)
8. Bickel PE 2002 Lipid rafts and insulin signaling. American Journal of Physiology. Endocrinology and Metabolism 282 E1-E10.
9. Bid HK, Zhan J, Phelps DA, Kurmasheva RT & Houghton PJ 2012 Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2. Molecular Cancer Therapeutics 11 649-659. (doi:10.1158/1535-7163.MCT-11-0575)
10. Blakesley VA, Scrimgeour A, Esposito D & Le Roith D 1996 Signaling via the insulin-like growth factor-I receptor: does it differ from insulin receptor signaling? Cytokine & Growth Factor Reviews 7 153-159. (doi:10.1016/1359-6101(96)00015-9)
11. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Lerner L, Chiu MI, Wild R & Epstein D 2010 Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Molecular Cancer Therapeutics 9 2652-2664. (doi:10.1158/1535-7163.MCT-10-0318)
12. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT & Koo H 2003 A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks liganddependent signaling and inhibits human tumor growth in vivo. Cancer Research 63 8912-8921.
13. Dupont J, Khan J, Qu B-H, Metzler P, Helman L & LeRoith D 2001 Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142 4969-4975. (doi:10.1210/endo.142.11.8476)
14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale C-M, Zhao X & Christensen J 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 1039-1043. (doi:10.1126/science.1141478)
15. Fernández AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI & Le Roith D 2001 Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes and Development 15 1926-1934. (doi:10.1101/gad.908001)
16. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S & LeRoith D 2010 Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes. Endocrine-Related Cancer 17 941-951. (doi:10.1677/ERC-10-0091)
17. Gallagher EJ & LeRoith D 2010 The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metabolism 21 610-618. (doi:10.1016/j.tem.2010.06.007)
18. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B & Hood N 2002 Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. Journal of Clinical Oncology 20 42-51. (doi:10.1200/JCO.20.1.42)
19. Guha M 2013 Anticancer IGF1R classes take more knocks. Nature Reviews. Drug Discovery 12 250-250. (doi:10.1038/nrd3992)
20. Huang J, Morehouse C, Streicher K, Higgs BW, Gao J, Czapiga M, Boutrin A, Zhu W, Brohawn P, Chang Y et al. 2011 Altered expression of insulin receptor isoforms in breast cancer. PLoS ONE 6 e26177. (doi:10.1371/journal.pone.0026177)
21. Judson J, Wyk V, Graves DC, Casella SJ & Jacobs S 1985 Evidence from monoclonal antibody studies that insulin stimulates deoxyribonucleic acid synthesis through the type I somatomedin receptor. Journal of Clinical Endocrinology and Metabolism 61 639-643. (doi:10.1210/jcem-61-4-639)
22. Kristiansen G, Sammar M & Altevogt P 2004 Tumour biological aspects of CD24, a mucin-like adhesion molecule. Journal of Molecular Histology 35 255-262. (doi:10.1023/B:HIJO.0000032357.16261.c5)
23. Lim S-C & Oh S-H 2005 The role of CD24 in various human epithelial neoplasias. Pathology, Research and Practice 201 479-486. (doi:10.1016/j.prp.2005.05.004)
24. Mathieu MC, Clark GM, Allred DC, Goldfine ID & Vigneri R 1997 Insulin receptor expression and clinical outcome in node-negative breast cancer. Proceedings of the Association of American Physicians 109 565-571.
25. de la Monte SM & Wands JR 2005 Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. Journal of Alzheimer's Disease 7 45-61.
26. Noto H, Goto A, Tsujimoto T, Osame K & Noda M 2013 Latest insights into the risk of cancer in diabetes. Journal of Diabetes Investigation 4 225-232. (doi:10.1111/jdi.12068)
27. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, Carboni JM, Gottardis MM, Pennisi PA & Molinolo AA 2010 Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Research 70 741-751. (doi:10.1158/0008-5472.CAN-09-2141)
28. Peairs KS, Barone BB, Snyder CF, Yeh H-C, Stein KB, Derr RL, Brancati FL &Wolff AC 2011 Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. Journal of Clinical Oncology 29 40-46. (doi:10.1200/JCO.2009.27.3011)
29. Pei XF, Noble MS, Davoli MA, Rosfjord E, Tilli MT, Furth PA, Russell R, Johnson MD & Dickson RB 2004 Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice. In Vitro Cellular & Developmental Biology. Animal 40 14-21. (doi:10.1290/1543-706X(2004)40〈14:ECOPMT〉2.0.CO;2)
30. + breast cancer-initiating cells to radiation. Journal of the National Cancer Institute 98 1777-1785. (doi:10.1093/jnci/djj495)
31. Pike LJ 2003 Lipid rafts: bringing order to chaos. Journal of Lipid Research 44 655-667. (doi:10.1194/jlr.R200021-JLR200)
32. Rome S, Clément K, Rabasa-Lhoret R, Loizon E, Poitou C, Barsh GS, Riou J-P, Laville M & Vidal H 2003 Microarray profiling of human skeletal muscle reveals that insulin regulates ∼800 genes during a hyperinsulinemic clamp. Journal of Biological Chemistry 278 18063-18068. (doi:10.1074/jbc.M300293200)
33. Rostoker R, Bitton-Worms K, Caspi A, Shen-Orr Z & LeRoith D 2013 Investigating new therapeutic strategies targeting hyperinsulinemia's mitogenic effects in a female mouse breast cancer model. Endocrinology 154 1701-1710. (doi:10.1210/en.2012-2263)
34. Rowzee AM, Ludwig DL & Wood TL 2009 Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells. Endocrinology 150 3611-3619. (doi:10.1210/en.2008-1473)
35. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T & Arber N 2008 Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Research 68 2803-2812. (doi:10.1158/0008-5472.CAN-07-6463)
36. Saltiel AR & Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 799-806. (doi:10.1038/414799a)
37. Sampson EM, Haque ZK, Ku MC, Tevosian SG, Albanese C, Pestell RG, Paulson KE & Yee AS 2001 Negative regulation of the Wnt-β-catenin pathway by the transcriptional repressor HBP1. EMBO Journal 20 4500-4511. (doi:10.1093/emboj/20.16.4500)
38. Sementchenko VI, Schweinfest CW, Papas TS & Watson DK 1998 ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 17 2883-2888. (doi:10.1038/sj.onc.1202220)
39. Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, Tomlins SA, Kristiansen G & Theodorescu D 2012 CD24 Is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Research 72 5600-5612. (doi:10.1158/0008-5472.CAN-11-3666)
40. Vaillant F, Asselin-Labat M-L, Shackleton M, Forrest NC, Lindeman GJ &Visvader JE 2008 The mammary progenitor marker CD61/β3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis. Cancer Research 68 7711-7717. (doi:10.1158/0008-5472.CAN-08-1949)
41. Vainio S, Heino S, Mansson JE, Fredman P, Kuismanen E, Vaarala O &Ikonen E 2002 Dynamic association of human insulin receptor with lipid rafts in cells lacking caveolae. EMBO Reports 3 95-100. (doi:10.1093/embo-reports/kvf010)
42. Weinstein D, Sarfstein R, Laron Z & Werner H 2014 Insulin receptor compensates for IGF1R inhibition and directly induces mitogenic activity in prostate cancer cells. Endocrine Connections 3 24-35. (doi:10.1530/EC-13-0086)
43. + cells with cancer stem cell characteristics. Breast Cancer Research 10 R10. (doi:10.1186/bcr1855)
44. Yang Y & Yee D 2012 Targeting insulin and insulin-like growth factor signaling in breast cancer. Journal of Mammary Gland Biology and Neoplasia 17 251-261. (doi:10.1007/s10911-012-9268-y)
45. Zhang H, Pelzer AM, Kiang DT & Yee D 2007 Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Research 67 391-397. (doi:10.1158/0008-5472.CAN-06-1712)
46. Zhang XH-F, Jin X, Malladi S, Zou Y, Wen YH, Brogi E, Smid M, Foekens JA & Massague J 2013 Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 154 1060-1073. (doi:10.1016/j.cell.2013.07.036)